Abstract:It is possible to repress amyloid precursor protein (APP) mRNA translation as a novel anti-amyloid pharmacotherapy for Alzheimer's Disease (AD). This therapeutic model is consistent with well-documented cases where AD pathology can be the genetic consequence of duplications of the APP gene. This genetic duplication caused increased brain APP dose leading to over-expression of Ab amyloid and then disease onset. These findings support our pharmacological goal to reduce APP expression. As due diligence, we showed that FDA drugs (i.e., paroxetine & N-acetyl cysteine) selectively reduced APP translation in neural and epithelial cells while maintaining compensatory APLP-1/-2 levels, but then these drugs also limited Aß production in vivo. Paroxetineis a well-known selective serotonin reuptake inhibitor (SSRI) and a clinical anti-depressant that was identified to inhibit APP 5'untranslated region (5'UTR)-luciferase reporter expression. We showed proof-of-concept that unlike other SSRIs, paroxetine exhibits a planar tricyclic aromatic benzodioxole structure and provided anti-amyloid activity in the brains of APP(Swe) transgenic mice. Additionally, posiphen, a + enantiomer of the well-tested anti-cholinesterase phenserine, passed phase I clinical trials for AD as an APP 5'UTR inhibitor. Encouraged by this, we screened the 110,000 compound molecular library at Harvard's Laboratory for Drug Discovery in Neurodegenerative Diseases that had been optimized to obtain pharmacologically favorable activity agents; for example small molecules that inhibit mesangial cell proliferation following three-dimensional pharmacophore modeling. From our screen, thirteen top leads shared chemical features pertinent to their potently blocking APP 5'UTR directed translation (IC-50: 1nM to ∼100nM). This correlated well with their selective suppression of APP expression in several neural cell lines. The top compounds of these APP 5'UTR inhibitors were 50-fold more potent blockers of Aß precursor translation than either paroxetineor posiphen. The most active lead was the ninth compound in the series, APP blocker-9 (“JTR-009”). Critically, JTR-009 effectively reduced APP levels in primary mouse E-18 cortical neurons at single nanomolar concentrations similar to that for the serum concentrations of effective clinical drugs. Our top APP translation blocker, JTR-009, is a planar tricyclic benzimidazole that could potentially intercalate into the single 146 base APP 5'UTR specific RNA stem loop. Confirming specificity, we are checking how JTR-009 blocks ribosome scanning of the APP 5'UTR to impede translation (Aß output) but not to interact with the 5'UTRs of APP-like protein (APLP-1/-2) mRNAs. We are currently determining the in vivo pharmacokinetics and tolerance of JTR-009, and we are completing a structure activity relationship (SAR) study of ten close analogs using primary cortical neurons from the B6-R1.40 genomic mouse model of AD.

Alzheimer’s disease drug discovery targeted to the APP mRNA 5′Untranslated region

Drug discovery targeted to the Alzheimer's APP mRNA 5'-untranslated region: the action of paroxetine and dimercaptopropanol

[P‐199]: Alzheimer's Disease Drug Discovery Targeted to the APP Mrna 5′ Untranslated Region, Paroxetine Proof‐of‐concept for a Validated Target

Specific APP translation blockers as a therapeutic intervention for Alzheimer's disease

P2‐497: Mechanism of Action of App Translation Blockers: from Model to Human

Therapeutic Action of Translation Blockers on Expression of the Amyloid Precursor Protein As a Central Ferroxidase

RNA Therapeutics Directed to the Non Coding Regions of APP Mrna, in Vivo Anti-Amyloid Efficacy of Paroxetine, Erythromycin, and N-acetyl Cysteine.

Novel 5 ' Untranslated Region Directed Blockers of Iron-Regulatory Protein-1 Dependent Amyloid Precursor Protein Translation: Implications for Down Syndrome and Alzheimer'S Disease

Targeting Amyloidogenic Processing of APP in Alzheimer’s Disease

Pilot Study of the Reducing Effect on Amyloidosis in Vivo by Three FDA Pre-Approved Drugs Via the Alzheimer's APP 5' Untranslated Region.

Progress in the Development of Nonpeptidomimetic BACE 1 Inhibitors for Alzheimers Disease

Amyloid binding and beyond: a new approach for Alzheimer's disease drug discovery targeting Aβo-PrPC binding and downstream pathways

Computational Drug Repurposing for Alzheimer’s Disease Using Risk Genes From GWAS and Single-Cell RNA Sequencing Studies

Network Proximity-based computational pipeline identifies drug candidates for different pathological stages of Alzheimer's disease

P4-402 Alzheimer's Disease Drug Discovery Targeted to the APP MRNA 5′ Untranslated Region, a Validated Target

Targeting Iron Responsive Elements (IREs) of APP mRNA into Novel Therapeutics to Control the Translation of Amyloid-β Precursor Protein in Alzheimer's Disease

An over Expression App Model for Anti-Alzheimer Disease Drug Screening Created by Zinc Finger Nuclease Technology

A Drug Repositioning Approach Reveals Ergotamine May Be a Potential Drug for the Treatment of Alzheimer's Disease

A Drug Repositioning Approach Reveals Ergotamine May Be a Potential Drug for the Treatment of Alzheimer’s Disease

Discovery of a Novel Pharmacological and Structural Class of Gamma Secretase Modulators Derived from the Extract of Actaea Racemosa.

Drugs for Targeted Therapies of Alzheimer’s Disease